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Background: The aim of this study was to determine the prognostic significance of right
ventricular dilation on CT pulmonary angiogram in acute pulmonary embolism and to distin-
guish if this feature predicts mortality independently of the Pulmonary Embolism Severity
Index, an established admission severity score.
Methods: A retrospective study of patients admitted with pulmonary embolism confirmed by
CT pulmonary angiogram to three teaching hospitals in East Scotland between January 2005
and July 2007. Two radiologists judged presence of right ventricular dilation on CT pulmonary
angiogram independently. The outcome of interest was 30 day mortality. Multivariable logistic
regression was used to compare this outcome in patients with right ventricular dilation
compared to those without right ventricular dilation, adjusting for Pulmonary Embolism
Severity Index score.
Results: There were 585 patients included and 30.4% had right ventricular dilation on CT
pulmonary angiogram. Patients with right ventricular dilation had increased 30 day mortality
rates compared to patients without right ventricular dilation (12.4% vs. 5.4%; pZ 0.006).
Survival analysis showed that a significantly greater proportion of deaths in the right ventric-
ular dilation group occurred within the first 48 h after admission compared to the group
without right ventricular dilation (45.5% deaths vs. 9.1%; pZ 0.016). On multivariable analysis,
adjusting for Pulmonary Embolism Severity Index score, right ventricular dilation was indepen-
dently associated with increased 30 day mortality (OR 2.98; 95% CI 1.54e5.75; pZ 0.001).10423273; fax: þ44 1312421870.
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of 30 day mortality in acute pulmonary embolism.
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Severity assessment is an important component of the initial
management of patients presenting with acute pulmonary
embolism (PE). Recently there has been a trend towards
classification of patients into three risk groups. Patients with
‘high risk PE’ are those who develop haemodynamic insta-
bility, with high risk of mortality and may benefit from
thrombolytic therapy1,2 while those with ‘low risk PE’ have
no haemodynamic instability and are at lower risk of adverse
outcome. A separate sub-group of patients exists with
‘intermediate risk PE’ (haemodynamically stable but with
evidence of right ventricular (RV) dysfunction). These
patients have been shown to have higher rates of mortality
in some studies but not in all case series3,4 and the role for
thrombolysis in this group is unclear.5,6
Various methods are available to admitting clinicians to
assess for presence of RV dysfunction in patients with PE.
Clinical examination features (e.g. raised jugular venous
pressure, parasternal heave) and electrocardiographic find-
ings (e.g. T wave inversion in right precordial leads, right
bundle branch block, S1Q3T3 complex) have some value but
are known to be unreliable for accurate detection of RV
dysfunction.7,8 More accurate prognostic information can be
obtained by use of transthoracic echocardiography which
can reliably identify the presence of RV dysfunction.4,9e12
However, in many hospitals, a 24-h echocardiography
service is often not available and this modality also suffers
from technical difficulties of imaging the right heart,
particularly when used by less experienced operators.13
Serum biomarkers, such as troponin and brain-natriuetic
peptide have also been shown to correlate with presence
of RV injury in PE14,15 but these tests appear to be more
useful for their negative predictive value of excluding RV
injury rather than for prediction.13
More recently, there has been interest in CT-pulmonary
angiographic (CTPA) features of right ventricular
dysfunction such as right ventricle/left ventricle (RV/LV)
ratio.16e19 Comparative studies have shown that CTPA
compares favourably with echocardiography for evalua-
tion of right ventricular dilation in acute PE20e22 and is
also predictive of outcome.18,23,24 CTPA may thus be
a more convenient method than echocardiography for
detecting RV dilation in clinical practice, as the majority
of patients with suspected PE will undergo this investiga-
tion for diagnostic purposes.
The pulmonary embolism severity index (PESI) is
a recently developed tool derived to aid in risk stratifica-
tion of patients presenting with PE.25,26 However, despite
RV dysfunction being associated with adverse outcome,
PESI does not incorporate its assessment. Recent guidelines
have advocated use of alternative scoring systems that
consider presence of RV dysfunction as a predictive factor.1
The aim of this study was to determine the prognostic
significance of RV dilation on CTPA in patients presentingwith acute PE and to distinguish if this feature predicts
mortality independently of PE Severity Index (PESI criteria).
Methods
A retrospective study of patients admitted to the emer-
gency department, with acute PE in three teaching hospi-
tals in East of Scotland between January 2005 and July
2007. We included all patients admitted with acute
pulmonary embolism, confirmed by CT pulmonary angio-
gram. The study was approved by the Lothian Ethics
Research Committee.
Exclusion criteria were: Cardiac arrest or cardiogenic
shock without confirmed PE diagnosis; A history of a known
thrombotic disorder, thrombophilia or haematological
malignancy; Ongoing therapeutic anticoagulation at time of
admission; Patients not actively treated with anticoagulation
(palliative care).
Data collection
Baseline demographics (age, sex), admission vital signs
(pulse, blood pressure, respiratory rate, temperature,
arterial oxygen saturations on room air) and clinical infor-
mation (comorbidities and exclusion criteria) were
collected on a standardised data collection pro-forma. All
parameters recorded were measured within 4 h of admis-
sion and the earliest available measurement was used. This
information was used to retrospectively calculate PESI class
on admission for each patient, as previously described25
(see Appendix 1). Missing data was assumed to be normal
in keeping with the methodology in previous studies26 and
less than 1% missing data was encountered in this study.
Radiological investigation
All patients had pulmonary embolism confirmed by CTPA.
The CT scans were all performed using a 16 slice multi-
detector CT scanner. The presence or absence of RV dila-
tion and proximal extension of thrombus, visible on CTPA
was judged and recorded independently by two experi-
enced radiologists, with any disagreements resolved by
discussion. RV dilation was defined as presence of the
following previously described feature: right/left ventricle
ratio 1.16e18 The right/left ventricle ratio was obtained by
measuring the ratio between the widths of the right and
left ventricular cavities on axial images obtained at plane
of maximal distance between the ventricular endocardial
free wall and the interventricular septum, perpendicular to
the long axis, as previously described.23
Outcomes
The primary outcome of interest was 30-day mortality.
Table 1 Characteristics of study population and comparison with existing studies.
Baseline characteristic Current study National studies
Aujesky et al.25 Jimenez et al.27 Wicki et al.28
Number of patients 585 10,354 599 268
Gender (% males) 43.0% 33.6% 46.1% 48.3%
Age> 65 years 55.4% 52.8% 67.0% 67.2%
Cardiac failure 14.9% 16.1% 8.0% 34.8%
Chronic lung disease 15.4% 18.2% 10.5% 14.9%
Malignancy 18.8% 19.9% 23.4% 18.2%
Pulse 110/min 27.4% 29.2% 19.4% 24.2%
Systolic blood pressure< 100 mmHg 11.5% 10.6% 8.7% 2.7%
Respiratory rate 30/min 16.8% 14.5% 5.0% 19.3%
Temperature< 36 C 2.7% 16.7% 6.2% Not assessed
Confusion 3.1% 6.9% 0% Not assessed
Arterial oxygen saturations< 90% on air 8.2% 8.0% 23.7% Not assessed
Data presented as % number of patients.
Right ventricular dilation on CT predicts mortality in PE 1059Treatment and follow-up
All patients received standard treatment for acute
pulmonary embolism with initial anticoagulation by
weight-adjusted low molecular weight heparin while
being converted to oral vitamin K antagonist therapy.
After completing 5 days of low molecular weight heparin,
all patients were continued on dose-adjusted oral vitamin
K antagonist therapy [warfarin; target international nor-
malised ratio (INR) of 2.5 (therapeutic range 2.0e3.0)].
Thrombolytic therapy with recombinant tissue plasmin-
ogen activator (rtPA) was administered to patients with
PE presenting with cardiogenic shock and/or persistent
arterial hypotension, in accordance with current
guidelines.1
Survival status was assessed at 30 days for patients who
were still an in-patient at this time point or at six week
outpatient follow-up, if discharged before day 30. For any
patient who did not attend outpatient follow-up, survival
status was obtained by reviewing general practitioner
records. Survival status was confirmed in 100% of patients
included in the study.Table 2 Characteristics of patients with and without RV dilatio
Baseline characteristic RV dilation on
(nZ 178)
Gender (% males) 44.9%
Age> 65 years 51.7%
Congestive cardiac failure 15.7%
Chronic lung disease 14.0%
Malignancy 19.1%
Pulse 110/min 36.0%
Systolic blood pressure< 100 mmHg 21.3%
Respiratory rate > 30/min 23.0%
Temperature< 36 C 3.9%
Confusion 6.7%
Arterial oxygen saturations< 90% on air 13.5%
30 day mortality 12.4%
PESI score> 3 32.6%
% Receiving thrombolysis 3.9%Statistical analysis
All data was analysed and processed on SPSS version 13.0
for windows (SPSS Inc., Chicago, IL). Descriptive statistics
of demographic and clinical variables are expressed as % of
group unless otherwise stated. The Chi squared test was
used to compare categorical data between groups. Kaplan
Meier analysis was used for comparison of survival between
patients with RV dilation and those without RV dilation. The
statistical significance was evaluated using the log-rank
test. We used multivariable logistic regression to compare
30-day mortality rates between patients with PE with RV
dilation, compared to patients with PE and no RV dilation.
To the baseline model, we included PE Severity Index (PESI
criteria) e non-severe (3) vs. severe (4). All variables
were coded as binary data for use in the model. A two-
tailed p value <0.05 was considered statistically significant.
Results
There were 585 patients who met the criteria and were
included in the study. Baseline characteristics of the studyn.
CTPA No RV dilation on CTPA
(nZ 407)
p Value
43.7% 0.79
57.0% 0.24
14.5% 0.61
16.0% 0.62
18.7% 0.91
26.6% 0.003
7.1% <0.0001
14.0% 0.008
2.2% 0.27
1.5% 0.001
5.9% 0.003
5.4% 0.006
21.6% 0.007
0% 0.0002
Figure 1 Kaplan meier survival Analysis in patients with RV
dilation.
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acute PE (see Table 1). A total of 72% of patients had CT
pulmonary angiogram performed within 24 h of admission.
There were 30.4% of patients with evidence of RV dila-
tion on CT pulmonary angiogram. There were 1.2% of
patients who received thrombolysis. Baseline characteris-
tics in patients with and without RV dilation are summar-
ised in Table 2. On admission, patients with evidence of RV
dilation on CTPA had significantly increased rates of
tachycardia (pulse 110/min), hypotension (systolic blood
pressure< 100mmHg), tachypnoea (respiratory rate 30/
min), hypoxia (arterial oxygen saturations on room
air< 90%) and confusion, when compared to patients with
no RV dilation. A greater proportion of patients with RV
dilation were classified as severe according to PESI score
(class 4 or 5), compared to patients without RV dilation
(32.6% vs. 21.6%; pZ 0.007) (see Table 2).
Right ventricular dilation and correlation with PESI
Distribution of patients according to PESI criteria was: class
1: 23.4%; class 2: 25.8%; class 3: 25.8%; class 4: 14.2%; class
5: 10.8%. Increasing mortality rates were observed with
increasing PESI class for both patients with RV dilation on
CTPA and patients with no RV dilation (see Table 3). A trend
towards increased mortality rates was observed in patients
with RV dilation compared to those with no RV dilation
when stratified according to PESI risk class, although no
significant differences were observed between the two
groups (see Table 3).
Right ventricular dilation and correlation with
proximal extension of thrombus
Overall, 22.7% patients with PE had main pulmonary artery
thrombus, 62.2% had lobar or segmental thrombus and 15.1%
had subsegmental thrombus. Right ventricular dilation was
present in 77.4% of patients with main pulmonary artery PE,Table 3 Thirty day mortality rates in patients with RV
dilation compared to those with no RV dilation, stratified
according to PESI risk class. Data presented as % of
subgroup.
RV dilation No RV dilation p Value*
n % Mortality n % Mortality
PESI class 1
(nZ 137)
29 3.4% 108 0% 0.21
PESI class 2
(nZ 151)
44 4.5% 107 2.8% 0.63
PESI class 3
(nZ 151)
47 10.6% 104 7.7% 0.54
PESI class 4
(nZ 83)
28 14.3% 55 9.1% 0.48
PESI class 5
(nZ 63)
30 33.3% 33 18.2% 0.25
p Value** 0.002 <0.0001
*p Value compares RV dilation vs. no RV dilation groups; **p value
compares rates across PESI classes.compared to 20.3% of patients with lobar/segmental
thrombus and 1.1% of patients with subsegmental thrombus.
(p< 0.0001).
Survival analysis
A significantly greater proportion of deaths in the RV
dilation group occurred within the first 48 h after
admission compared to the group without RV dilation
(45.5% deaths in RV dilation group vs. 9.1% deaths in
group without RV dilation; pZ 0.016). Fig. 1 shows
Kaplan Meier survival analysis in patients with RV dilation
and in those without RV dilation, for 30 days post
admission. In patients with RV dilation, mortality
occurred earlier, in comparison to those without RV
dilation (Comparison of curves: Log rankZ 6.4 on 1
degree of freedom; pZ 0.011).
Right ventricular dilation on CTPA as a predictor of
30 day mortality
Univariable analysis
The overall 30-day mortality rate was 7.5%. Patients with
RV dilation on CTPA had significantly increased rates of 30
day mortality compared with patients with no RV dilation
(12.4% vs. 5.4%; pZ 0.006).
Multivariable analysis
On multivariable analysis, adjusting for PESI score, RV
dilation on CTPA was independently associated with
increased 30 day mortality (OR 2.98; 95% CI 1.54e5.75;
pZ 0.001) (see Table 4).Table 4 Multivariable analysis.
Variable Adjusted odds
ratio
95% Confidence
interval
p Value
RV dilation 2.98 1.54e5.75 0.001
PESI 4 3.51 1.68e7.33 0.0008
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chronic lung disease or chronic cardiac failure
As right ventricular dilationmaybemore frequent in patients
with chronic lung disease and chronic cardiac failure,
a separate analysis was performed excluding these patients.
Overall, 25.8% had a history of chronic lung disease or cardiac
failure (or both). Among the remaining population that did
not have a history of either chronic lung disease or cardiac
failure, the frequency of RV dilation was 28.8%. Thirty-day
mortality in this sub-groupwas also higher in patientswith RV
dilation compared to those without RV dilation (9.6% vs.
2.9%, pZ 0.006). Onmultivariable analysis, in the sub-group
without chronic lung disease and/or cardiac failure, RV
dilation was independently associated with 30 day mortality
(OR 2.59; 95% CIZ 1.02e6.54; pZ 0.04).
Discussion
The results of this study show that, in patients with acute
PE, the presence of RV dilation assessed on CTPA is inde-
pendently associated with increased risk of 30 day
mortality, after adjustment for PESI criteria.
The PE severity index is a well validated prediction rule
that considers 11 clinical and demographic variables and has
been proposed as a tool for identifying low risk patients who
may be suitable for outpatient therapy.25,26 Despite RV
dysfunction being associated with increased mortality risk,
prediction rules such as PESI donot consider assessment of RV
dysfunction as a predictive factor. Clinicians should consider
RV dysfunction along with other markers of severity when
risk-stratifying patients with acute PE and our results vali-
date the view that RV dilation on CTPA can beused to identify
patients at increased risk of adverse outcomes. Recent
guidelines have also recognised the importance of identifi-
cation of RV dysfunction in PE and have thus advocated use of
alternative scoring systems which consider its assessment as
a predictive parameter.1
In this study, we defined RV dysfunction based on cardiac
measurement (right ventricle/left ventricle ratio 1). This
parameter has beenconsistently shown tobea reliablemarker
of acute RV dysfunction in PE.29 Other studies have considered
alternative features on CTPA such as clot load scores,30 reflux
of contrast into the inferior vena cava,19,20,31 pulmonary
artery diameter,16,24 and bowing of the interventricular
septum16,19,24 but theseparameters areeither less accurate or
too complex for use in clinical practice.29 RV/LV ratio 1 is
a simple, reliable feature that can be identified by clinicians
and general radiologists, without the need for complicated
radiological measurements and is thus ideally suited to use in
clinical practice.RV/LVratio 1was specifically chosen in this
study as it is the cutoff that has been most commonly used to
define RV dilation in the literature.29 However, some studies
haveused slightly different cutoffs suchasRV/LVratio 0.9.18
Current guidelines advocate use of echocardiography to
identify signs of RV dysfunction1 as it offers the advantage of
allowing a real-time functional assessment of the right
ventricle, in contrast to CTPA which only gives information on
right ventricular morphology. However, echocardiography has
limited availability at many institutions and occasionally the
right ventricle may be difficult to image with this modality,
particularlywhenassessedbya less experiencedoperator.13 Inaddition, despite having good predictive accuracy for identi-
fication of RV dysfunction, echocardiography has poor
predictive value for diagnosis of PE.29 Therefore, other
modalities are required to confirm presence of PE, if echo-
cardiography is used to identify RV dysfunction. CTPA is
acommonlyuseddiagnostic test for suspectedPEand isusually
more readily available than echocardiography. Our results
suggest that, in addition to diagnostic purposes, CTPA could be
used to identify patients with PE at increased risk ofmortality,
by allowing an immediate assessment of the presence or
absence of RV dilation, without the need for additional tests.
The increased mortality observed in patients with RV
dysfunction, is thought to be caused by pressure overload of
the right ventricle secondary to acute pulmonary arterial
hypertension caused by PE. This leads to right ventricular
dysfunctionwhich thenultimately progresses toRV failureand
circulatory collapse.32 This hypothesis is further supported by
our finding that patients with RV dilation on CTPA had signif-
icantly increased evidence of markers of physiological
derangement such as tachycardia, hypotension and hypoxia.
Survival analysis of patients with RV dilation in our cohort
indicated that a high proportion of deaths in this group occur
early after admission (within 48 h). This reinforces that, in
patients with PE, RV dilation on CTPA is a feature that should
alert clinicians to a potential need for early aggressive
management strategies.
Our results suggest that RV dilation on CTPA may
represent an additional marker of severe PE and such
patients should be considered as being at increased risk of
adverse outcome. This is further confirmed by our finding
that patients with RV dilation were more likely to be clas-
sified in higher risk groups on the basis of admission severity
scoring (PESI criteria). However, RV dilation on CTPA was
a marker of poor outcome, independent of severity.
Assessment of the correlation of presence of RV dilation on
CTPA with thrombotic load (proximal extension of thrombus)
showed that a greater proportion of patients with thrombus in
mainpulmonaryarteries hadevidenceofRVdilation compared
to those with segmental and subsegmental thrombus. The
retrospective nature of this studymeant that correlation of RV
dilation with formal scoring systems of thrombotic burden,
such as the Miller score33 could not be evaluated.
This study is limited by its retrospective design. Prospec-
tive studies are preferable because of a reduced risk of
ascertainment bias. However, as studies of PE require a posi-
tive CTPA and we included consecutive patients undergoing
CTPA with confirmed PE, no cases of radiologically confirmed
PE were missed during the study period. The retrospective
nature of our analysis also prevented direct comparison of
CTPA determined RV dilation with echocardiographic assess-
ment, as no patients included in the current study had both
CTPA and echocardiography performed on admission.
In conclusion, this studyshows thatRVdilationonCTPA isan
independent predictor of increased mortality risk in patients
with acute PE. Potentially, CTPA assessment of RV dilation
could be used to identify higher-risk patients and guide
subsequent management but further studies are required.Conflict of interest statement
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